João pedro Alves Damaceno do lago

Mx. João pedro Alves Damaceno do lago

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 July 2026 in Naunyn-Schmiedeberg's Archives of Pharmacology
Verified
Journal Article
Open access
PDF file
VVVIVIANE LEAL VELOSO
VIVIANE LEAL VELOSO
WAWellington Dos Santos Alves
Wellington Dos Santos Alves
Damiao Pergentino de SousaDamiao Pergentino de Sousa
Damiao Pergentino de Sousa
JSJoão Marcelo de Castro e Sousa
João Marcelo de Castro e Sousa
FLFrancisco das Chagas Alves Lima
Francisco das Chagas Alves Lima
FOFrancisco Oliveira
Francisco Oliveira
Acute respiratory distress syndrome (ARDS) is a life-threatening inflammatory condition characterized by high morbidity and mortality, with limited effective pharmacological therapies currently available. The search for novel compounds with anti-inflammatory and antioxidant properties remains essential to improve clinical outcomes. In this context, Pentyl (2E)-3-(3-methoxyphenyl)prop-2-enoate (MAP), a phenolic cinnamic acid derivative, emerges as a promising candidate due to its potential biological activities. This study aimed to investigate the anti-inflammatory effects of MAP using an integrative approach combining in silico and in vivo analyses. Initially, pharmacokinetic and toxicological predictions indicated favorable oral bioavailability, adequate distribution, low predicted toxicity, and compliance with Lipinski’s rules. Molecular docking studies demonstrated significant interactions with key inflammation-related targets, while density functional theory (DFT) calculations revealed electronic stability and favorable orbital distribution. Additionally, molecular dynamics simulations confirmed the stability of ligand–protein complexes, with low root mean square deviation (RMSD) values over time. Subsequently, the in vivo effects of MAP were evaluated in a rat model of intestinal ischemia–reperfusion (iI/R)-induced ARDS. Oral administration of MAP (20, 40, or 60 mg/kg) significantly reduced leukocyte infiltration, oxidative stress markers, and pro-inflammatory cytokines (TNF-α, IL-1β, and IL-6) while attenuating histopathological lung damage. Furthermore, MAP enhanced antioxidant defenses by increasing glutathione levels and catalase activity, alongside reducing nitric oxide production. Importantly, no evidence of acute genotoxicity was observed at the tested doses. In summary, MAP demonstrated consistent anti-inflammatory and antioxidant effects across computational and experimental models, effectively mitigating key pathological features of ARDS. These findings suggest that MAP is a promising adjuvant therapeutic candidate for acute respiratory inflammatory conditions, although further studies are necessary to elucidate its mechanisms of action and support its potential clinical application. Graphical Abstract